Vanflyta

quizartinib

Approval

ApplicationNDA 216993
Approval dateJul 20, 2023
Approval year2023
SponsorDaiichi Sankyo INC

FDA-approved use

To use as part of a treatment regimen for newly diagnosed acute myeloid leukemia that meets certain criteria

Approval package

Query with Claude

The fda-analyst skill answers natural-language questions about this approval by fetching the relevant FDA review PDFs at query time.

git clone https://github.com/cbetz/trove
cp -r trove/skills/fda-analyst ~/.claude/skills/

Example prompts for Vanflyta: